| | | | | |

Breakthroughs in Mesothelioma in 2020

ByAlex Strauss
breakthroughs in mesothelioma

In spite of a global pandemic, there were some major breakthroughs in mesothelioma in 2020 that made the year a hopeful one for people fighting asbestos cancer.

Malignant mesothelioma is the most serious illness caused by exposure to asbestos fibers. 

Mesothelioma is still not curable. But researchers have made major breakthroughs in mesothelioma diagnosis, prognosis, and treatment this year. 

Mesothelioma Treatment Advances

Mesothelioma treatment saw the biggest breakthroughs in mesothelioma in 2020. The FDA approved the first systemic treatment for mesothelioma since 2004. That was the year that Alimta (pemetrexed) received approval. 

They approved a combination of the immunotherapy drugs Opdivo and Yervoy. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the mesothelioma  tumor. The patients who got the new drug combination for mesothelioma lived a median of 18 months. 

At one year, almost 70 percent of patients who got the immunotherapy drugs were still alive. Only 58 percent of chemotherapy patients lived that long. 

The second most important of the breakthroughs in mesothelioma treatment this year centers on Tumor Treating Fields. The electrical device received a new name in 2020. It is now Optune Lua. Optune Lua interrupts the replication of mesothelioma cells and stimulates the immune system. 

This summer, the makers of Optune Lua and the immunotherapy drug Keytruda announced that they are teaming up for a new study. The study is testing a combination of these treatments in non-small cell lung cancer patients. The results are likely to impact the future of mesothelioma treatment, too. 

Diagnostic Wins

One of the most significant breakthroughs in mesothelioma diagnosis was a biomarker study in July.  That study appeared to confirm the best biomarkers for mesothelioma diagnosis and prognosis. 

Two of the country’s top authorities on mesothelioma, Dr. Harvey Pass of New York’s Langone Medical Center and Dr. Michele Carbone of the University of Hawaii, were authors on the new report.

They conducted a major review of medical literature over the last 20 years. They concluded that SMRPs (Soluble Mesothelin Related Proteins) are the best diagnostic biomarkers for mesothelioma. SMRPs are also the most valuable biomarkers for monitoring the success of mesothelioma treatment. 

Other important diagnostic breakthroughs for mesothelioma were two reports on the use of artificial intelligence. 

One study came from the Stevens Institute of Technology and the other from Mount Sinai Medical Center in New York. Both suggest that machine learning –  which can identify patterns that doctors miss – may be the future of mesothelioma diagnosis and treatment planning. 

Breakthroughs in Mesothelioma Prognosis

International Immunopharmacology published the largest study ever on PD-L1 expression and mesothelioma prognosis. It showed that patients whose cells express more of this protein have lower odds of survival. 

Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack. 

Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But a meta-analysis performed by Chinese researchers confirmed it with an even bigger data set. 

Another of the breakthroughs in mesothelioma prognosis also centered on protein expression. This time, BAP1 was in the spotlight. Alterations of the BAP1 gene affect BAP1 expression. People with low levels of BAP1 appear to have a higher risk for mesothelioma. 

But a large Italian study released in July suggested that mesothelioma prognosis has more to do with subtype than with BAP1 expression. It cautioned doctors not to put too much stock in BAP1 expression without also considering other factors. 

Sources:

“FDA Approves Drug Combination for Treating Mesothelioma”, FDA Press Announcement, October 2, 2020, https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma

“Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Non-Small Cell Lung Cancer”, July 15, 2020, Novocure Website

Choudhury, A, “Predicting cancer using supervised machine learning: Mesothelioma”, June 19, 2020, Technology in Health Care, https://content.iospress.com/articles/technology-and-health-care/thc202237

Dumane, VA, et al, “RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma”, June 17, 2020, Practical Radiation Oncology, Epub ahead of print, https://www.practicalradonc.org/article/S1879-8500(20)30158-2/pdf

Pass, H, et al, “Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network”, July 22, 2020, Cancer Epidemiology, Biomarkers & Prevention, Epub ahead of print, https://cebp.aacrjournals.org/content/early/2020/07/22/1055-9965.EPI-20-0083

Zhang, F, and Gong, W, “Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis”, April 24, 2020, International Immunopharmacology, Epub ahead of print, https://www.sciencedirect.com/science/article/pii/S1567576920306639?via%3Dihub

Cantini, L, et al, “Questioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis”, June 21, 2020, Lung Cancer, Epub ahead of print, https://www.lungcancerjournal.info/article/S0169-5002(20)30498-0/pdf

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…